STOCK TITAN

Novavax (NVAX) EVP R&D discloses options, RSUs and shares on Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

NOVAVAX INC executive Robert Edward Walker, EVP, R&D, filed an initial ownership report showing equity awards and common stock holdings. The filing lists stock options to purchase 11,500 shares of common stock at $6.97 expiring on March 7, 2033, 22,510 shares at $10.11 expiring on March 3, 2035, and 18,826 shares at $8.39 expiring on March 2, 2036.

He also holds restricted stock units covering 47,600, 29,490 and 26,300 shares of common stock, plus 34,386 shares of common stock directly. Footnotes describe standard vesting schedules over three to four years, tied to continued employment.

Positive

  • None.

Negative

  • None.
Insider Walker Robert Edward
Role EVP, R&D
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Units -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Units -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Units -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 11,500 shares (Direct); Restricted Stock Units — 47,600 shares (Direct); Common Stock — 34,386 shares (Direct)
Footnotes (1)
  1. Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the March 7, 2023 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment with the Company through such vesting date. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the March 3, 2025 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 3, 2025 grant date, in each case subject to continued employment with the Company through such vesting date. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the March 2, 2026 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 2, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.
Option grant 1 11,500 shares at $6.97 Stock option, expires March 7, 2033
Option grant 2 22,510 shares at $10.11 Stock option, expires March 3, 2035
Option grant 3 18,826 shares at $8.39 Stock option, expires March 2, 2036
RSU grant 1 47,600 underlying shares Restricted Stock Units under Plan
RSU grant 2 29,490 underlying shares Restricted Stock Units under Plan
RSU grant 3 26,300 underlying shares Restricted Stock Units under Plan
Direct common stock 34,386 shares Directly held Novavax common stock
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with underlying common stock"
Restricted Stock Units financial
"security_title: "Restricted Stock Units" with underlying common stock shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Amended and Restated 2015 Stock Incentive Plan financial
"option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan"
vesting financial
"shares vested or will vest in equal monthly installments over three years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continued employment financial
"subject to continued employment with the Company through such vesting date"
Continued employment means that an individual remains in their current job without interruption. For investors, it signals stability and ongoing work that can affect company performance and future prospects. Like a steady heartbeat for a business, sustained employment helps ensure consistent operations and financial health.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Walker Robert Edward

(Last)(First)(Middle)
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD

(Street)
GAITHERSBURG MARYLAND 20878

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
04/14/2026
3. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, R&D
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock34,386D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (1)03/07/2033(1)Common Stock11,500$6.97D
Restricted Stock Units (2) (2)Common Stock47,600$0.00D
Stock Option (Right to Buy) (3)03/03/2035(3)Common Stock22,510$10.11D
Restricted Stock Units (4) (4)Common Stock29,490$0.00D
Stock Option (Right to Buy) (5)03/02/2036(5)Common Stock18,826$8.39D
Restricted Stock Units (6) (6)Common Stock26,300$0.00D
Explanation of Responses:
1. Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the March 7, 2023 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
2. The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment with the Company through such vesting date.
3. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the March 3, 2025 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
4. The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 3, 2025 grant date, in each case subject to continued employment with the Company through such vesting date.
5. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the March 2, 2026 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
6. The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 2, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Mark J. Casey, Attorney-in-Fact04/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Novavax (NVAX) Form 3 filing by Robert Edward Walker show?

The Form 3 shows EVP, R&D Robert Edward Walker’s initial equity holdings in Novavax, including stock options, restricted stock units (RSUs), and directly held common shares, providing transparency into his compensation-related ownership position at the company.

How many Novavax (NVAX) stock options does Robert Walker report on Form 3?

Robert Walker reports stock options linked to 11,500 shares at $6.97, 22,510 shares at $10.11, and 18,826 shares at $8.39 per share. These options expire on March 7, 2033, March 3, 2035, and March 2, 2036, respectively, and relate to Novavax common stock.

What restricted stock unit (RSU) holdings are disclosed for Robert Walker in Novavax (NVAX)?

He holds RSUs tied to 47,600, 29,490, and 26,300 Novavax common shares. Footnotes state these RSUs vest in one-third annual installments over three years from grant dates in March 2024 and March 2025, subject to continued employment with the company through each vesting date.

What are the vesting terms for Robert Walker’s Novavax (NVAX) stock options?

For each option grant, 25% of the shares vested on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting under the Novavax 2015 Stock Incentive Plan depends on continued employment at each vesting date.

How many Novavax (NVAX) common shares does Robert Walker directly own according to the Form 3?

The Form 3 reports that Robert Walker directly holds 34,386 shares of Novavax common stock. This figure reflects his direct ownership separate from stock options and restricted stock units, which represent additional potential or future share ownership subject to vesting and exercise.